Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer-Reference-Cited by-同舟云学术

Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer

Published:2019-07-08 Issue: Volume: Page:
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:J Surg Oncol

Author:

Liang Margaret I.¹²³^ORCID,Prendergast Emily N.¹²³,Staples Jeanine N.¹,Holschneider Christine H.³,Cohen Joshua G.²,Cass Ilana¹

Affiliation:

1. Division of Gynecologic Oncology, Department of Obstetrics and GynecologyCedars‐Sinai Medical CenterLos Angeles California

2. Division of Gynecologic Oncology, Department of Obstetrics and GynecologyUniversity of California Los Angeles Medical CenterLos Angeles California

3. Division of Gynecologic Oncology, Department of Obstetrics and GynecologyOlive View Hospital–University of California Los Angeles Medical CenterSylmar California

Publisher

Wiley

Subject

Oncology,General Medicine,Surgery

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jso.25612

Reference18 articles.

1. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of prospectively randomized phase 3 multicenter trials;du Bois A;Cancer,2009

2. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer;Vergote I;N Engl J Med,2010

3. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open‐label, randomized, controlled, non‐inferiority trial;Kehoe S;Lancet,2015

4. Phase III randomized clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri‐operative outcome;Fagotti A;Eur J Cancer,2016

5. Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States;Melamed A;Gynecol Oncol,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer;International Journal of Gynecologic Cancer;2022-07-20

2. Application of J‑Plasma in the excision of diaphragmatic lesions as part of complete cytoreduction in patients with advanced ovarian cancer;Molecular and Clinical Oncology;2022-05-18

3. Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer;Gynecologic Oncology;2022-04

4. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer;Gynecologic Oncology;2021-06

5. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer;Surgical Oncology;2021-06